PUBLISHER: Value Market Research | PRODUCT CODE: 1288895
PUBLISHER: Value Market Research | PRODUCT CODE: 1288895
Cell & gene therapy manufacturing services include comprehensive and seamless manufacturing and quality-testing services for cellular and gene therapy products. The service provider helps biotechnology & pharmaceutical companies and research groups boost translational and clinical discoveries and foster an environment of collaboration and innovation. Cell therapy manufacturing services include allogeneic, autologous, and viral vectors, while gene therapy manufacturing services non-viral vectors, oligonucleotides, and viral vectors. Cell & gene therapy manufacturing services provide flexible and pioneering tools to simplify workflow, innovation, scalability, customization, consistency, reproducibility, reducing risk, and navigate at every step of the manufacturing process.
Factors such as the high prevalence of cancer and chronic diseases, increasing spending in pharmaceutical & biological research, and increasing collaboration among companies and CDMOs are primarily driving the growth of the global cell & gene therapy manufacturing services market. Cell and gene therapies offer potential promise to treat and relieve life-threatening diseases. Pharmaceutical companies are massively investing in the development of new drugs and therapies. Pharmaceutical companies are more usually outsource their research CDMOs or CROs to focus on core activities. Moreover, Pharmaceutical companies find it challenging to do R&D with high quality and efficiency. Outsourcing stands out as the best approach to them. However, the high operational costs concerned with cell & gene therapy manufacturing are likely to restrain market growth to some extent.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cell & gene therapy manufacturing services. The growth and trends of cell & gene therapy manufacturing services industry provide a holistic approach to this study.
This section of the cell & gene therapy manufacturing services market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Cell & Gene Therapy Manufacturing Services market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cell & gene therapy manufacturing services market include Lonza (Switzerland), Catalent Inc. (US), Thermo Fisher Scientific Inc. (US), Charles River Laboratories (US), WuXi AppTec (China), Merck KGaA (Germany), Takara Bio Inc. (Japan), Oxford Biomedica (UK), Cell and Gene Therapy Catapult (UK), Genezen (US), FUJIFILM Holdings Corporation (Japan), Nikon Corporation (Japan), The Discovery Labs LLC (US), RoslinCT (Scotland), JRS Pharma (Germany), FinVector (Finland), ABL Inc. (US), Resilience (US), BioCentriq (US), Porton Advanced Solutions (China), Andelyn Biosciences (US), Forge Biologics (US), Vibalogics (US), Anemocyte Srl (Italy), ElevateBio (US) This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies